ROCKVILLE, Md., May 10, 2013 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) today reported its financial results for the three months ended March 31, 2013 and provided a business and clinical update.
"The Company continues to progress all of its clinical trial programs, in the U.S. and abroad, as we move into 2013. The FDA has approved our Phase II trial protocol for NSI-566/ALS, which we expect to initiate this summer. The protocol calls for an aggressive dose escalation strategy and adds a second trial center," said Karl Johe , PhD, Neuralstem's Chairman of the Board and Chief Scientific Officer. "We welcome our esteemed collaborators at University of Michigan joining our collaborators at Emory. We look forward to receiving approvals from both Institutional Review Boards in the near term and to commencing the trial, which has generous grant funding from the National Institutes of Health and ALSA.
"Institutional Review Board approvals are also expected during this summer for our NSI-566 chronic spinal cord injury trial, approved by the FDA in January. This trial uses the same cells and procedure proven safe and well-tolerated in the ALS trial. The ALS data was presented at the American Association of Neurological Surgeons Annual Meeting, in April," continued Dr. Johe. "The Phase I/chronic spinal cord injury trial will treat a total of eight patients with T2-T12 complete paralysis. The trial centers will be announced as the IRB approvals are obtained."
Dr. Johe commented further, "Internationally, the NSI-566 trial preparations are progressing well. We anticipate the Phase I/II ischemic stroke trial at BaYi Brain Hospital, in Beijing, will commence this quarter, representing the first-in-human direct stereotactic inje
|SOURCE Neuralstem, Inc.|
Copyright©2012 PR Newswire.
All rights reserved